ZIVO Bioscience, Inc.

ZIVO · Other OTC · USD

5,75USD

−0,25 (−4,17 %)Stand 10. Nov., 14:30

Vortag 6,00

Kennzahlen

Eröffnung
5,75
Vortag
6,00
Tagesspanne
5,75 – 5,75
52 Wochen
1,11 – 13,29
Volumen
13
Ø Volumen
845
Börsenwert
22,36 Mio. $
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
0,1
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

ZIVO Bioscience, Inc. is a research and development firm that specializes in the creation and commercialization of natural bioactive compounds. These unique ingredients, derived from its proprietary algae cultures, are licensed and sold to manufacturers producing goods for animal health, human consumption, dietary supplements, and medical foods. The company operates at the intersection of biotechnology and agricultural technology, boasting a comprehensive intellectual property portfolio. This includes distinct algal and bacterial strains, advanced biologically active molecules and complexes, innovative production and cultivation techniques, and various inventions, some patented and others pending approval, all geared towards improving human and animal well-being. Its product applications are broad, addressing areas such as promoting gut health in poultry, combating bovine mastitis, improving joint function in canines, modulating the human immune system, providing algal biomass for direct human consumption, and offering biomass-based solutions for skin care and anti-aging. Founded originally as Health Enhancement Products, Inc., the company officially rebranded to ZIVO Bioscience, Inc. in October 2014. Its corporate operations are based in Bloomfield Hills, Michigan.

CEO
John Bernard Payne
Mitarbeitende
7
Hauptsitz
Troy, MI, US
Sektor
Healthcare
Branche
Biotechnology
Börsengang
15. Dez. 2003

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.